- Clinical Trials
- April 2025
- 60 Pages
Global
From €1144EUR$1,250USD£972GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1144EUR$1,250USD£972GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1144EUR$1,250USD£972GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1144EUR$1,250USD£972GBP
- Report
- July 2024
- 100 Pages
Global
From €3433EUR$3,750USD£2,917GBP
- Drug Pipelines
- July 2024
- 100 Pages
Global
From €3433EUR$3,750USD£2,917GBP
- Report
- July 2024
- 150 Pages
Global
From €3433EUR$3,750USD£2,917GBP
- Report
- July 2024
- 100 Pages
Global
From €3433EUR$3,750USD£2,917GBP
- Report
- July 2024
- 100 Pages
Global
From €3433EUR$3,750USD£2,917GBP
- Report
- June 2024
- 200 Pages
Global
From €7277EUR$7,950USD£6,185GBP
- Report
- June 2024
- 200 Pages
Global
From €7277EUR$7,950USD£6,185GBP
- Report
- August 2024
- 150 Pages
Global
From €2553EUR$2,789USD£2,170GBP
- Report
- August 2024
- 200 Pages
Global
From €3542EUR$3,869USD£3,010GBP
- Report
- August 2024
- 200 Pages
Global
From €3542EUR$3,869USD£3,010GBP
- Report
- August 2024
- 150 Pages
Global
From €2553EUR$2,789USD£2,170GBP
- Report
- August 2024
- 150 Pages
Global
From €2553EUR$2,789USD£2,170GBP
- Report
- May 2024
- 140 Pages
Global
From €4530EUR$4,949USD£3,850GBP
- Clinical Trials
- April 2025
- 180 Pages
Global
From €2289EUR$2,500USD£1,945GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1144EUR$1,250USD£972GBP
- Drug Pipelines
- April 2025
- 80 Pages
Global
From €1831EUR$2,000USD£1,556GBP

T Cell Therapies are a type of biotechnology that involves the use of a patient's own T cells to treat diseases. T cells are a type of white blood cell that play a key role in the body's immune system. T Cell Therapies involve the extraction of T cells from a patient, engineering them to recognize and attack specific targets, and then reintroducing them into the patient's body. This type of therapy has been used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma. It has also been used to treat autoimmune diseases, such as rheumatoid arthritis and Crohn's disease.
T Cell Therapies are a rapidly growing field of biotechnology, with many companies investing in research and development. Companies such as Kite Pharma, Juno Therapeutics, and Novartis are leading the way in developing and commercializing T Cell Therapies. Other companies, such as Gilead Sciences, Celgene, and Regeneron, are also investing in the field. Show Less Read more